Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27780740 | 0.84 | TSHR (0.46) | TSHRALDH1A1KDM4EHTTLMNA | |
| SCHEMBL28626336 | 0.83 | TSHR (0.44) | TSHRALDH1A1KDM4EHTTLMNA | |
| SCHEMBL13664109 | 0.81 | TSHR (0.43) | TSHRALDH1A1KDM4EHTTLMNA | |
| SCHEMBL28058188 | 0.79 | TSHR (0.46) | TSHRALDH1A1KDM4EHTTLMNA | |
| SCHEMBL13664108 | 0.79 | ALDH1A1 (0.42) | TSHRALDH1A1KDM4EHTTLMNA | |
| SCHEMBL31360845 | 0.79 | TSHR (0.52) | TSHRALDH1A1KDM4EHTTLMNA | |
| SCHEMBL16379032 | 0.77 | TSHR (0.39) | TSHRALDH1A1KDM4EHTTLMNA | |
| SCHEMBL13324326 | 0.76 | KDM4E (0.49) | TSHRALDH1A1KDM4EHTTLMNA | |
| SCHEMBL12051760 | 0.76 | TSHR (0.46) | TSHRALDH1A1KDM4EHTTLMNA | |
| SCHEMBL10196371 | 0.75 | TSHR (0.53) | TSHRALDH1A1HTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | BCAT1, BCAT2, AADAT | TSHR 3260/4885ALDH1A1 837/4885KDM4E 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.